Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company focused on the development of cleverly-designed medicines with precise mechanisms of action to improve the lives of patients with the most difficult-to-treat cancers.
Location: Canada
Employees: 51-200
Total raised: $75M
Founded date: 2014
Investors 3
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | OrbiMed | orbimed.co... |
| - | Adams Stre... | adamsstree... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.09.2015 | Series B | $75M | - |
Mentions in press and media 11
| Date | Title | Description |
| 02.05.2024 | Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering | - |
| 13.03.2024 | Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024 | Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the ... |
| 13.03.2024 | Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024 | - |
| 27.09.2022 | Angel Pharmaceuticals Announces Approval of IND Application for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China | JIAXING,China and BURLINGAME,Calif., Sept. 27, 2022 /PRNewswire/ -- Angel Pharmaceuticals Ltd. ("Angel Pharma"), a clinical-stage biopharmaceutical company, today announced that the IND application for mupadolimab (formerly CPI-00... |
| 26.10.2021 | Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818 | JIAXING, China and BURLINGAME, Calif., Oct. 26, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the C... |
| 17.08.2021 | Angel Pharmaceuticals Announces IND Acceptance for Clinical Trial of ITK Inhibitor CPI-818 in China | JIAXING, China and BURLINGAME, Calif., Aug. 17, 2021 /PRNewswire/ -- Angel Pharmaceuticals Ltd. ("Angel Pharma") today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 04.01.2016 | Biotech Startups Hit the Ground Running, With Six Filing IPO Plans Today | If we had to gamble on it, we’d bet the IPO market will be far more brisk this year than last year, which was the worst year for tech IPOs in particular since 2009. Even still, it came as a bit of a surprise today when not one or three but ... |
| 29.09.2015 | Corvus Pharmaceuticals Closes $75M Series B Financing | Corvus Pharmaceuticals, a Burlingame, CA-based clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, closed a $75m Series B financing. The round was le... |
| 25.09.2015 | Former Pharmacyclics CEO raises $75M Series B for new immunotherapy startup Corvus | This new round, ostensibly a Series B, has 33 investors participating. The company has yet to return outreach to discuss the company’s activities, and how it’ll use the funding. OrbiMed Advisors led December’s Series A, though other investo... |
Show more